StockData
Lantheus Holdings, Inc. logo

Lantheus Holdings, Inc. (LNTH) stock analysis

LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3010% above fair value
$101.60−0.02 (-0.02%)

Close on Nov 11, 2026Market cap $6.63BP/E 25.1Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth2Performance5Health5Dividend0

Mixed12 of 30 checks passed

Lantheus passes 12 of the 30 checks behind our score; 8 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
5/6
Financial health
5/6
Dividend
0/6

What stands out

  • Return on equity over 15%

    Return on equity was 21.8% over the last twelve months and averaged 19.5% over five years.

  • Return on capital over 10%

    Return on invested capital was 18.0%, above the 10% that usually covers the cost of capital.

  • Revenue growing 10%+ a year

    Revenue grew 18.1% a year over the last three fiscal years.

  • EPS growing 10%+ a year

    Diluted EPS grew 104% a year over the last three fiscal years.

What to watch

  • Margin of safety under 20%

    The price is 10.0% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $101.60 is above our fair value estimate of $92.33.

  • High debt

    Debt is 42.2% of shareholders' equity, above the 40% we consider low.

  • P/E above its 5-year median

    Lantheus's P/E of 25.1 is above its own 5-year median of 24.2.

Valuation0/6

  • P/E above its 5-year median

    Lantheus's P/E of 25.1 is above its own 5-year median of 24.2.

  • P/E above the industry

    Lantheus's P/E of 25.1 is above the Drugs median of 25.1.

  • EV/EBITDA above its 5-year median

    Lantheus's EV/EBITDA of 17.1 is above its 5-year median of 14.6.

  • P/B above the industry

    Lantheus's price-to-book of 4.89 is above the Drugs median of 2.29.

  • Trading above fair value

    The share price of $101.60 is above our fair value estimate of $92.33.

  • Margin of safety under 20%

    The price is 10.0% above fair value, so there is no margin of safety.

Growth2/6

  • Revenue growing 10%+ a year

    Revenue grew 18.1% a year over the last three fiscal years.

  • EPS growing 10%+ a year

    Diluted EPS grew 104% a year over the last three fiscal years.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew 2.4% over the last twelve months; the Drugs median is 8.0%.

  • Guidance unchanged

    The latest outlook (FY 2026 FY 2026 Revenue, May 7, 2026) was maintained, so it neither adds nor takes away points.

  • Gross margin slipping

    Gross margin was 61.3% over the last twelve months, against 62.2% a year earlier.

Past performance5/6

  • Return on equity over 15%

    Return on equity was 21.8% over the last twelve months and averaged 19.5% over five years.

  • Return on capital over 10%

    Return on invested capital was 18.0%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Lantheus's return on equity of 21.8% is above the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 17.3% over the last twelve months, against a 5-year average of 9.4%.

  • Net margin above the industry

    Lantheus's net margin of 17.3% is above the Drugs median of -53.0%.

Financial health5/6

  • High debt

    Debt is 42.2% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 42.5% five years ago to 42.2%.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 71.6% of total debt.

  • Interest well covered

    Operating income covers interest expense 14.7 times.

  • Short-term assets cover short-term debts

    Current assets are 3.25 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 5.53; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Lantheus has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$92.33

The share price is 10% above this estimate.

20%+ below
Near fair value
20%+ above
$101.60Price
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E24.6×24.2×25.1×$99.7240%
EV/EBITDA15.9×14.6×17.1×$94.5035%
P/B4.1×5.8×2.3×$84.3710%
Earnings power8.4% cost of equity––$72.8815%
Fair value$92.33100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 24.2
  • Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$100.83M
Value traded per 1% price move
$456.04M

Downside

Low risk

Typical loss in a bad month
6.8%
Volatility (annualized)
31%
Sharpe ratio, 1 year
3.12
Beta to the S&P 500 (5Y)
0.70

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2012 to 2025

Gross margin

61.1%+20.2 pts over 5 years

Operating margin

20.2%+21.4 pts over 5 years

Net margin

15.2%+19.1 pts over 5 years

See a number that looks wrong?